nach oben

Erschienen in:

17.10.2015 | Original Article

Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer

verfasst von: Xiaosheng He, Xutao Lin, Muyan Cai, Xiaobin Zheng, Lei Lian, Dejun Fan, Xiaojian Wu, Ping Lan, Jianping Wang

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

It has been suggested that hexokinase 1 (HK1) is involved in tumorigenesis. However, the expression dynamics of HK1 and its prognostic significance in human colorectal cancer (CRC) still remain unclear. The aim of the present study was to investigate the expression of HK1 and its prognostic significance in CRC. In this study, immunohistochemical analysis was used to examine the expression dynamics of HK1 in CRC tissues from two independent cohorts. Receiver operating characteristic curve analysis, Kaplan–Meier curves, and Cox regression analysis were utilized to investigate the prognostic significance. Results showed that a high expression of HK1 was observed in 106 of 393 (27.0 %) and 69 of 229 (30.1 %) of CRC in the training cohort and validation cohort, respectively. Further correlation analyses indicated that the increased HK1 expression was strongly correlated with the pN classification and TNM stage. Both cohorts showed a close association between the overexpression of HK1 and poorer overall survival. Importantly, multivariate analysis identified HK1 expression in CRC as an independent prognostic factor. Overexpression of HK1 may act as a significant biomarker of poor prognosis for patients with CRC.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. Br J Cancer. 2008;99 Suppl 1:S30–2.CrossRefPubMedPubMedCentral

Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer. 2012;131:1649–58.CrossRefPubMed

Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106:130–7.CrossRefPubMed

Zou Y, Chen Y, Wu X, Yuan R, Cai Z, He X, et al. CCL21 as an independent favorable prognostic factor for stage III/IV colorectal cancer. Oncol Rep. 2013;30:659–66.PubMed

Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170–8.PubMed

Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem. 2003;10:1535–51.CrossRefPubMed

Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab. 2005;90:328–34.CrossRefPubMed

Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N. Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. Breast Cancer Res Treat. 2011;126:55–62.CrossRefPubMed

10.

Oparina NY, Snezhkina AV, Sadritdinova AF, Veselovskii VA, Dmitriev AA, Senchenko VN, et al. Differential expression of genes that encode glycolysis enzymes in kidney and lung cancer in humans. Genetika. 2013;49:814–23.PubMed

11.

Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Investig. 1986;55:244–8.PubMed

12.

Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60:1112–6.CrossRefPubMed

13.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMed

14.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.CrossRefPubMed

15.

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.CrossRefPubMedPubMedCentral

16.

Huang Y, Li W, Chu D, Zheng J, Ji G, Li M, et al. Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer. J Gastrointest Surg. 2011;15:1188–94.CrossRefPubMed

17.

Lin KY, Tai C, Hsu JC, Li CF, Fang CL, Lai HC, et al. Overexpression of nuclear protein kinase CK2 alpha catalytic subunit (CK2alpha) as a poor prognosticator in human colorectal cancer. PLoS One. 2011;6, e17193.CrossRefPubMedPubMedCentral

18.

Lin AY, Chua MS, Choi YL, Yeh W, Kim YH, Azzi R, et al. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One. 2011;6, e16636.CrossRefPubMedPubMedCentral

19.

Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24:68–72.CrossRefPubMed

20.

Oronsky BT, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, et al. Follow the ATP: tumor energy production. A perspective. Anticancer Agents Med Chem. 2014.

21.

Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB. Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem. 2002;277:11392–400.CrossRefPubMed

22.

Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J. 2004;377:347–55.CrossRefPubMedPubMedCentral

23.

Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H. Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol. 2008;28:1007–17.CrossRefPubMed

24.

Maldonado EN, Lemasters JJ. Warburg revisited: regulation of mitochondrial metabolism by voltage-dependent anion channels in cancer cells. J Pharmacol Exp Ther. 2012;342:637–41.CrossRefPubMedPubMedCentral

25.

Colombini M. VDAC structure, selectivity, and dynamics. Biochim Biophys Acta. 1818;2012:1457–65.

26.

Takahashi Y, Tateda C. The functions of voltage-dependent anion channels in plants. Apoptosis. 2013;18:917–24.CrossRefPubMed

27.

Martel C, Wang Z, Brenner C. VDAC phosphorylation, a lipid sensor influencing the cell fate. Mitochondrion. 2014.

28.

Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315–28.CrossRefPubMedPubMedCentral

29.

Bhatia B, Potts CR, Guldal C, Choi S, Korshunov A, Pfister S, et al. Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathol. 2012;123:587–600.CrossRefPubMedPubMedCentral

30.

Wolf A, Agnihotri S, Munoz D, Guha A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis. 2011;44:84–91.CrossRefPubMed

31.

Clatot F, Gouerant S, Mareschal S, Cornic M, Berghian A, Choussy O, et al. The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol. 2014;50:200–7.CrossRefPubMed

32.

Li W, Xu Z, Hong J, Xu Y. Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival. Med Oncol. 2014;31:118.CrossRefPubMed

33.

Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3, e103.CrossRefPubMedPubMedCentral

34.

Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154–66.CrossRefPubMedPubMedCentral

35.

Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014.

36.

Beck JT, Ismail A, Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014;40:980–9.CrossRefPubMed

Titel: Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer
verfasst von: Xiaosheng He
Xutao Lin
Muyan Cai
Xiaobin Zheng
Lei Lian
Dejun Fan
Xiaojian Wu
Ping Lan
Jianping Wang
Publikationsdatum: 17.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4255-8

Springer Medizin

Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population

MicroRNA-101 polymorphisms and risk of head and neck squamous cell carcinoma in a Chinese population

Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors

S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2

Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway

Alpha-linolenic acid regulates Cox2/VEGF/MAP kinase pathway and decreases the expression of HPV oncoproteins E6/E7 through restoration of p53 and Rb expression in human cervical cancer cell lines

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie